Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $275.70M.
ENTERPRISE VALUE (EV)
$275.70M
Akebia Therapeutics, Inc.
Market Cap
$244.25M
Enterprise Value (EV)
$275.70M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $244.25M | $275.70M |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | $370.08M |
| InflaRx N.V. (IFRX)vs › | $247.45M | $81.07M |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | $239.33M |
| High Tide Inc. (HITI)vs › | $239.89M | $294.34M |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | $168.32M |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | $166.88M |
| Biodesix, Inc. (BDSX)vs › | $236.56M | $278.36M |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | $208.82M |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | $248.95M |
Market Cap
$244.25M
Total Debt
$216.30M
Cash
$184.84M
Enterprise Value
$275.70M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
